RNaseH2 inhibition potentiates temozolomide response in patient derived glioblastoma cells

Abstract Glioblastoma (GBM) is the most common and lethal form of primary brain tumor, characterized by poor prognosis and limited treatment options, with a median survival of only 12 to 15 months post-diagnosis. Despite standard therapeutic protocols involving temozolomide (TMZ) and radiotherapy, e...

Descripció completa

Dades bibliogràfiques

Autors principals:	Miroslava Kissova, Judit Martinez Segarra, Tobias Solli Iveland, Marthe Vestvik, Erlend Ravlo, Wei Wang, Lars Hagen, Nina-Beate Liabakk, Maria Camara-Quilez, Miquel Arano Barenys, Ole Solheim, Bård Helge Hoff, Eirik Sundby, Magnar Bjørås, Geir Slupphaug, Torkild Visnes, Alessandro Brambilla
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-11-01
Col·lecció:	Scientific Reports
Matèries:	GBM High-throughput screening (HTS) Drug screening
Accés en línia:	https://doi.org/10.1038/s41598-025-25298-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!